[April 08, 2014] |
|
PeptiDream Announces the Development of a New Broad Strain Anti-Influenza Macrocyclic Peptide Therapeutic
TOKYO --(Business Wire)--
PeptiDream Inc., a public Tokyo-based biopharmaceutical company
("PeptiDream")( TOKYO:4587) announced today, in collaboration with The
Tokyo Metropolitan Institute of Medical Science ("Tokyo Metropolitan
Institute") the discovery and development of a novel macrocyclic peptide
inhibitor for the treatment of multiple influenza strains.
Tokyo Metropolitan Institute has been leading a broad-based discovery
effort for novel treatments for influenza, funded by the Japanese
government and initiated in 2008. PeptiDream joined the discovery
consortium taking a peptide-based approach using PeptiDream's
proprietary Peptide Discovery Platform System (PDPS) to identify novel
macrocyclic peptide inhibitors for influenza.
Two marketed therapeutics, Relenza (GSK) and Tamiflu (Roche), inhibit
the neuraminidase enzyme on the influenza virus surface, yet these
therapeutics are only effective shortly after viral exposure and are
less effective against newer influenza strains, thus there is immediate
need for other more effective treatments with different mechanisms of
action.
The partnership focused on the discovery of novel peptide inhibitors of
the influenza hemagglutinin (HA) protein found on the surface of
influenza viruses and responsible for the binding and entry of viru to
cells. PeptiDream identified lead peptide candidate iHA-24 which
exhibited high affinity and selectivity for the HA protein. In addition,
the macrocyclic peptide was highly effective in preventing both viral
infection and viral proliferation in both cell-based experiments and
mouse-based animal studies, and was more effective than any commercially
available treatments. Peptide iHA-24 also exhibited broad influenza
strain efficacy against H1N1 (2009 pandemic strain), H5N1 (bird flu,
SARS), and H2N2 strains.
In light of these breakthrough results, pre-clinical testing in
cynomolgus monkeys is slated to begin in May 2014. Successful validation
of efficacy will lead to the preparation of a complete preclinical
development data package for investigational new drug (IND) application
slated for 2015.
[Comments from Dr. Michinori Kohara, Director of Viral Infectious
Disease Project at Tokyo Metropolitan Institute of Medical Science]
"We have been working for some time to develop an antibody
therapeutic to treat influenza targeting the HA protein, and PeptiDream
provided an attractive alternative by developing a peptide therapeutic,
capable of recognizing antigenic regions that conventional antibodies
cannot reach because of their significantly larger size. iHA-24
was found to exhibit inhibition activity equal to or even higher than
that of the current neuraminidase inhibitors. In addition, we
showed that iHA-24 could effectively inhibit the pandemic H1N1 2009
strain, of which some variants were resistant to neuraminidase
therapeutics. These exciting findings establish peptide therapy
as new anti-viral agents for the treatment of influenza. We
intend to continue pre-clinical testing in monkey trials, while we
rapidly prepare for clinical testing."
[Comments from Kiichi Kubota, CEO of PeptiDream Inc]
"We believe our macrocylic peptides represent an exciting new
approach to more effectively treating influenza virus, and also toward
the prevention of future influenza outbreaks. In collaboration
with Dr. Kohara's team, we are excited to start preclinical testing in
monkeys with the aim of bringing these peptides into human testing in
2015. This program represents one of the many exciting discovery and
development programs progressing at PeptiDream, and we would like to
thank Dr. Kohara and the staff at the Tokyo Metropolitan Institute of
Medical Science for all of their efforts."
[ Back To TMCnet.com's Homepage ]
|